Key Clinical Message
The novel time-limited combinations with the bcl-2 inhibitor Venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient.
Keywords: CLL/SLL, Venetoclax, time-limited therapy, skin nodules, MRD negativity